PMN (ProMIS Neurosciences) Beginning Cash Position: $6.12 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMN ProMIS Neurosciences Inc PMN
34 GF Score
Price $15.59
! 2 Warning Signs
View Full Analysis

What is ProMIS Neurosciences Beginning Cash Position?

ProMIS Neurosciences PMN +14.20% 34 Beginning Cash Position is $6.12 Mil as of Mar. 2026. GuruFocus rates PMN with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

ProMIS Neurosciences's Beginning Cash Position for the quarter that ended in Mar. 2026 was $6.12 Mil.

ProMIS Neurosciences's quarterly Beginning Cash Position declined from Sep. 2025 ($25.46 Mil) to Dec. 2025 ($15.40 Mil) and declined from Dec. 2025 ($15.40 Mil) to Mar. 2026 ($6.12 Mil).

ProMIS Neurosciences's annual Beginning Cash Position increased from Dec. 2023 ($5.88 Mil) to Dec. 2024 ($12.60 Mil) and increased from Dec. 2024 ($12.60 Mil) to Dec. 2025 ($13.29 Mil).

ProMIS Neurosciences Beginning Cash Position Related Terms

ProMIS Neurosciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for ProMIS Neurosciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProMIS Neurosciences Beginning Cash Position Chart

ProMIS Neurosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 16.94 5.88 12.60 13.29

ProMIS Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.29 8.36 25.46 15.40 6.12
PMN
34GF Score
ProMIS Neurosciences Inc PMN
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProMIS Neurosciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $6.12 Mil mean?
ProMIS Neurosciences (PMN) has a Beginning Cash Position of $6.12 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on ProMIS Neurosciences and its competitors.
Is ProMIS Neurosciences' Beginning Cash Position too high?
ProMIS Neurosciences' current Beginning Cash Position is $6.12 Mil. Overall, ProMIS Neurosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' Beginning Cash Position compare to BMEA and ANIX?
ProMIS Neurosciences' Beginning Cash Position of $6.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on ProMIS Neurosciences and its competitors. ProMIS Neurosciences's current Beginning Cash Position is $6.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current Beginning Cash Position of $6.12 Mil. The current Beginning Cash Position is $6.12 Mil. ProMIS Neurosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current Beginning Cash Position is $6.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProMIS Neurosciences Business Description

Other Exchanges 23J:Germany
Address 1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
34GF Score

Get the complete analysis for PMN

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.59
Price